Melatonin Inhibits Dengue Virus Infection via the Sirtuin 1-Mediated Interferon Pathway

• Main Authors: Atthapan Morchang, Shilu Malakar, Kanchanaphan Poonudom, Sansanee Noisakran, Pa-thai Yenchitsomanus, Thawornchai Limjindaporn
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Viruses
• Subjects: melatonin; dengue virus infection; DENV; sirtuin 1 (SIRT1)-mediated interferon (IFN) pathway
• Online Access: https://www.mdpi.com/1999-4915/13/4/659

Dengue virus (DENV) is the causative pathogen in the life-threatening dengue hemorrhagic fever and dengue shock syndrome. DENV is transmitted to humans via the bite of an infected <i>Aedes</i> mosquito. Approximately 100 million people are infected annually worldwide, and most of those live in tropical and subtropical areas. There is still no effective drug or vaccine for treatment of DENV infection. In this study, we set forth to investigate the effect of melatonin, which is a natural hormone with multiple pharmacological functions, against DENV infection. Treatment with subtoxic doses of melatonin dose-dependently inhibited DENV production. Cross-protection across serotypes and various cell types was also observed. Time-of-addition assay suggested that melatonin exerts its influence during the post-entry step of viral infection. The antiviral activity of melatonin partly originates from activation of the sirtuin pathway since co-treatment with melatonin and the sirtuin 1 (SIRT1) inhibitor reversed the effect of melatonin treatment alone. Moreover, melatonin could modulate the transcription of antiviral genes that aid in suppression of DENV production. This antiviral mechanism of melatonin suggests a possible new strategy for treating DENV infection.